Exosomes as promising frontier approaches in future cancer therapy DOI
Felix S. Chew,

Chin-Hung Tsai,

Kuang‐Hsi Chang

et al.

World Journal of Gastrointestinal Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: Dec. 11, 2024

In this editorial, we will discuss the article by Tang et al published in recent issue of World Journal Gastrointestinal Oncology . They explored an innovative approach to enhancing gemcitabine (GEM) delivery and efficacy using human bone marrow mesenchymal stem cells (HU-BMSCs)-derived exosomes. The manufacture GEM-loaded HU-BMSCs-derived exosomes (Exo-GEM) has been optimized. ’s study demonstrated that Exo-GEM exhibits enhanced cytotoxicity apoptosis-inducing effects compared free GEM, highlighting potential exosome-based drug systems as a more effective targeted chemotherapy pancreatic cancer. Additional vivo studies are required confirm safety effectiveness before it can be considered for clinical use.

Language: Английский

Innovative landscapes in intraperitoneal therapy of ovarian cancer DOI
K. Kumar,

M. S. Madhusoodanan,

Meghna Pangath

et al.

Drug Delivery and Translational Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 31, 2025

Language: Английский

Citations

1
The latest applications of exosome-mediated drug delivery in anticancer therapies DOI

Zhiwei Wen,

Wei Zhang, Wei Wu

et al.

Colloids and Surfaces B Biointerfaces, Journal Year: 2025, Volume and Issue: 249, P. 114500 - 114500

Published: Jan. 6, 2025

Language: Английский

Citations

0
The Role of Non-coding RNAs in Diabetic Retinopathy: Mechanistic Insights and Therapeutic Potential DOI

Zhuan Zuo,

Ni Li, Qian Zhang

et al.

Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Harnessing Extracellular Vesicles for Targeted Drug Delivery in Ovarian Cancer DOI Creative Commons
Jang‐Hyuk Yun,

Yoo Rim Noh,

Seongkyeong Yoo

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(4), P. 528 - 528

Published: April 17, 2025

Ovarian cancer remains one of the most lethal gynecologic malignancies, primarily due to late-stage diagnosis, high recurrence rates, and development chemoresistance. Although targeted therapies have improved patient outcomes, their efficacy is often limited by off-target toxicity acquired drug resistance. Extracellular vesicles (EVs), nanoscale naturally released cells, emerged as promising carriers for precision delivery. This review provides a comprehensive overview recent advances in EV-based therapeutic strategies ovarian cancer, including delivery chemotherapeutic agents, nucleic acid therapeutics, immunomodulatory molecules. We further explore innovative engineering approaches enhance targeting specificity, such surface modification, cell source selection, biomaterial integration, magnetic nanoparticle-assisted Key translational challenges bringing clinical application are also addressed. Collectively, these insights underscore transformative potential platforms advancing personalized treatment cancer.

Language: Английский

Citations

0
Exosomes: Key Factors in Ovarian Cancer Peritoneal Metastasis and Drug Resistance DOI Creative Commons
Ming Shao,

Yunran Gao,

Xiling Xu

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(9), P. 1099 - 1099

Published: Sept. 2, 2024

Ovarian cancer remains a leading cause of death among gynecological cancers, largely due to its propensity for peritoneal metastasis and the development drug resistance. This review concentrates on molecular underpinnings these two critical challenges. We delve into role exosomes, nano-sized vesicles integral cellular communication, in orchestrating complex interactions within tumor microenvironment that facilitate metastatic spread thwart therapeutic efforts. Specifically, we explore how exosomes drive by promoting epithelial–mesenchymal transition mesothelial cells, altering extracellular matrix, supporting angiogenesis, which collectively enable dissemination cells across cavity. Furthermore, dissect mechanisms contribute emergence resistance, including sequestration expulsion chemotherapeutic agents, horizontal transfer resistance genes, modulation DNA repair apoptotic pathways. By shedding light exosome-mediated processes, underscore potential exosomal pathways as novel targets, offering hope more effective interventions against ovarian cancer’s relentless progression.

Language: Английский

Citations

2
Cancer-associated Fibroblasts-derived Exosomes with HOXD11 Overexpression Promote Ovarian Cancer Cell Angiogenesis Via FN1 DOI
Chunfei Chen, Fahui Wang,

Chunling Cheng

et al.

Reproductive Sciences, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 11, 2024

Language: Английский

Citations

1
Emerging strategies to overcome ovarian cancer: advances in immunotherapy DOI Creative Commons
Tatiana Massariol Pimenta, Josiany Carlos de Souza, Bárbara da Silva Martins

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 5, 2024

Ovarian cancer is the second most common malignant neoplasm of gynecological origin and leading cause death from in female reproductive system worldwide. This scenario largely due to late diagnoses, often advanced stages, development chemoresistance by cells. These challenges highlight need for alternative treatments, with immunotherapy being a promising option. Cancer involves triggering an anti-tumor immune response developing immunological memory eliminate cells, prevent recurrence, inhibit metastasis. Some ongoing research investigate potentially advancements field vaccines, checkpoint blockade, CAR-T cell, other strategies.

Language: Английский

Citations

1
Exosomes as promising frontier approaches in future cancer therapy DOI
Felix S. Chew,

Chin-Hung Tsai,

Kuang‐Hsi Chang

et al.

World Journal of Gastrointestinal Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: Dec. 11, 2024

In this editorial, we will discuss the article by Tang et al published in recent issue of World Journal Gastrointestinal Oncology . They explored an innovative approach to enhancing gemcitabine (GEM) delivery and efficacy using human bone marrow mesenchymal stem cells (HU-BMSCs)-derived exosomes. The manufacture GEM-loaded HU-BMSCs-derived exosomes (Exo-GEM) has been optimized. ’s study demonstrated that Exo-GEM exhibits enhanced cytotoxicity apoptosis-inducing effects compared free GEM, highlighting potential exosome-based drug systems as a more effective targeted chemotherapy pancreatic cancer. Additional vivo studies are required confirm safety effectiveness before it can be considered for clinical use.

Language: Английский

Citations

0